Progress in the development of selective inhibitors of Aurora kinases

Current Topics in Medicinal Chemistry

Volumn 5, Issue 8, 2005, Pages 807-821

  Mortlock, Andrew A ^a   Keen, Nicolas J ^a   Jung, Frederic H ^a   Heron, Nicola M ^a   Foote, Kevin M ^a   Wilkinson, Robert W ^a   Green, Stephen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Aurora A; Aurora B; Cell cycle; Centrosome; Cytokinesis; Histone H3; Kinase inhibition; Mitosis; Polyploidy

Indexed keywords

5 AMINOPYRIMIDINOQUINAZOLINE DERIVATIVE; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; AURORA A; AURORA B; AURORA C; AURORA KINASE INHIBITOR; CELL CYCLE PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; HESPERADIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; THIAZOLYL 5 ACETANILIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE PHASE; COLON TUMOR; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; IN VITRO STUDY; LEUKEMIA; MITOSIS; NONHUMAN; PANCREAS TUMOR; PHENOTYPE; REGULATORY MECHANISM; REVIEW; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 23944488863     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054637719     Document Type: Review

References (72)

1. Adams, R.R.; Carmena, M.; Earnshaw, W.C. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 2001, 11, 49-54.
2. Nigg, E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2, 21-32.
3. Bischoff, J.R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souzza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C.S.M.; Novotny, M.; Slamon, D.J.; Plowman, G.D. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998, 17, 3052-3065.
4. Anand, S.; PenrhynLowe, S.; Venkitaraman, A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3, 51-62.
5. Hauf, S.; Cole, R.W.; LaTerra, S.; Zimmer, C.; Schnapp, G.; Walter, R.; Heckel, A.; van Meel, J.; Rieder, C.L.; Peters, J-M. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 2003, 161, 281-294.
6. Kallio, M.J.; McCleland, M.L.; Stukenberg,P.T.; Gorbsky, G.J. Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr. Biol. 2002, 12, 900-905.
7. Ditchfield, C.; Johnson, V.L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor S.S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161, 267-280.
8. Carmena, M.; Earnshaw, W.C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 2003, 4, 842-854.
9. Hirota, T.; Kunitoku, N.; Sasayama, T.; Marumoto, T.; Zhang, D.; Nitta, M.; Hatakeyama, K.; Saya, H. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114, 585-598.
10. Meraldi, P.; Honda, R.; Nigg, E.A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 2002, 21, 483-492.
11. Kimura, M.; Matsuda, Y.; Yoshioka, T.; Okano,Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/lpl1-related protein kinase, AIK3. J. Biol. Chem. 1999, 274, 7334-7340.
12. Royce, M,E,; Xia, W.;, Sahim, A.A.; Katayama.; H, Johnston, D.A.; Hortobagyi, G.; Sen, S.; Hung, M.C. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004, 100, 12-19.
13. Miyoshi,Y.; Iwao,K.; Egawa, C.; Noguchi, S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int. J. Cancer 2001, 92, 370-373.
14. Sakakura, C.; Hagiwara, A.; Yasuoka, R.; Fujita, Y.;, Nakanishi, M.; Masuda, K.; Shimomura, K.; Nakamura Y.; Inazawa J.; Abe T.; Yamagishi, H. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br. J. Cancer 2001, 84, 824-831.
15. Ewart-Toland, A.; Briassouli, P.; de Koning J.P.; Mao, J.H.; Yuan, J.; Chan, F.; MacCarthy-Morrogh, L.; Ponder, B.A.; Nagase, H.; Burn, J.; Ball, S.; Almeida, M.; Linardopoulos, S.; Balmain, A. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. 2003, 34, 403-412.
16. Zhou, H.; Kuang, J.; Zhong, L.; Kuo, W.L.; Gray, J.W.; Sahin, B.R.; Brinkley, B.R.; Sen, S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 1998, 20, 189-193.
17. MurataHori, M.; Wang, Y.L. The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Curr. Biol. 2002, 12, 894-899.
18. Li,F. Survivin study: what is the next wave? J. Cell. Physiol. 2003, 197, 8-29.
19. Harrington, E.A.; Bebbington, D.; Moore, J.; Rasmussen, R.K.; Ajose-Adeogun, A.O.; Nakayama, T.; Graham, J.A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J.M.C.; Miller, K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Medicine 2004, 10, 262-267;
20. Harrington, L. VX-680, a novel small molecule inhibitor of the aurora kinases, suppresses tumour growth in vivo, AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA 2003.
21. Andreassen, P.R.; Lohez, O.D.; Lacroix, F.B.; Margolis, R.L. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol. Biol. Cell 2001, 12, 1315-1328.
22. Marumoto, T.; Honda, S.; Hara, T.; Nitta, M.; Hirota, T.; Kohmura, E.; Saya, H Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J. Biol. Chem. 2003, 278, 51786-51795.
23. Anderson, M.; Keen, N.J.; Pannifer, A.D.B.; Pauptit, R.A.; Rowsell, S. Crystal structure of human Aurora A kinase catalytic domain complexed with ATP analog and inhibitor and applications to structure-based drug design. WO2003031606 A2 20030417 CAN 138: 316772 AN 2003: 301212.
24. Cheetham, G.; Knegtel, R.; Swenson, L.; Coll, J.T.; Renwick, S.; Weber, P. Crystal structure of human Aurora-2 kinase complexes with ligands and their binding sites, and applications in drug screening and drug design. WO2003092607 A2 20031113 CAN 139: 377257 AN 2003:892555.
25. Cheetham, G.M.T.; Knegtel, R.M.A.; Coll, J.T.; Renwick, S.B.; Swenson, L.; Weber, P.; Lippke, J.A.; Austen, D.A. Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. 2002, 277, 42419-42422.
26. Nowakowski, J.; Cronin, C.N.; McRee, D.E.; Knuth, M.W.; Nelson, C.G.; Pavletich, N.P.; Rogers, J.; Sang, B-C.; Scheibe, D.N.; Swanson, R.V.; Thompson, D.A. Structures of the Cancer-Related Aurora A, FAK, and EphA2 Protein Kinases from Nanovolume Crystallography. Structure 2002, 10, 1659-1667.
27. Bayliss, R.; Sardon, T.; Vernos, I.; Conti, E. Structural Basis of Aurora-A Activation by TPX2 at the Mitotic Spindle. Mol. Cell 2003, 12, 851-862.
28. For reviews of kinase structural biology see: (a) Johnson, L.N.; Lowe, E.D.; Noble, M.E.M.; Owen, D.J. The structural basis for substrate recognition and control by protein kinases. FEBS Letts. 1998, 430, 1-11.
29. (b) Adams, J.A. Kinetic and Catalytic mechanisms of protein kinases. Chem. Rev. 2001, 101, 2271-2290.
30. Harrington, E.A.; Bebbington, D.; Moore, J.; Rasmussen, R.K.; Ajose-Adeogun, A.O.; Gladwell, S.; Dawson, D.A.; Furey, B.; Ma, J.; Firestone, B.; Nakayama, T.; Graham, J.A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Yao, Y-M.M.; Su, M.; Golec, J.M.C.; Miller, K.M. Abstract # LB-238, VX-680, A Novel Small Molecule Of The Aurora Kinases, Suppresses Tumour Growth in vivo, 95th AACR Annual Meeting, Orlando, Florida, USA, 2004.
31. Charrier, J.-D.; Mazzei, F.K.; Kay, D.; Miller, A.; Processes for preparing 6-pyrazolylpyrimidines as inhibitors of protein kinase, in particular Aurora kinases, by nucleophilic substitution. WO 2004000833 A1 20031231 CAN 140:59657 AN 2004:2878.
32. Bebbington, D.; Charrier, J.-D.; Golec, J.M.C.; Miller, A.; Knegtel, R. Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002062789 A1 20020815 CAN 137:169539 AN 2002:615605.
33. Bebbington, D.; Charrier, J-D.; Davies, R.; Golec, J.M.C.; Kay, D.; Knegtel, R.; Patel, S. Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002059111 A2 20020801 CAN 137:109292 AN 2002:575069.
34. Bebbington, D.; Charrier, J-D.; Davies, R.; Everitt, S.; Kay, D.; Knegtel, R.; Patel, S. Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3,for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002050065 A2 20020627 CAN 137:47221 AN 2002:487556.
35. Bebbington, D.; Charrier, J-D.; Golec, J.M.C.; Miller, A.; Knegtel, R. Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3. WO 2002057259 A2 20020725 CAN 137:125169 AN 2002:555487.
36. Davies, R.; Bebbington, D.; Binch, H.; Knegtel, R.; Golec, J.M.C.; Patel, S.; Charrier, J-D.; Kay, D.; Davies, R. Preparation of 3-(4-pyrimidinylamino) pyrazole derivatives as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease. WO 2002022604 A1 20020321 CAN 136:247606 AN 2002:220580.
37. Bebbington, D.; Charrier, J-D. Preparation of pyrazole compounds useful as protein kinase inhibitors, and therapeutic use thereof. WO 2002059112 A2 20020801 CAN 137:119705 AN 2002:575070.
38. Golec, J.M.C.; Pierard, F.; Charrier, J-D.; Bebbington, D. Pyrazole compounds useful as protein kinase inhibitors, and therapeutic use thereof. WO 2002050066 A2 20020627 CAN 137:57588 AN 2002:487557.
39. Bebbington, D.; Knegtel, R.; Golec, J.M.C.; Li, P.; Davies, R.; Charrier, J-D. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022608 A1 20020321 CAN 136:247584 AN 2002:220584.
40. Davies, R.; Bebbington, D.; Knegtel, R.; Wannamaker, M.; Li, P.; Forester, C.; Pierce, A.; Kay, D. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022607 A1 20020321 CAN 136:247583 AN 2002:220583.
41. Bebbington, D.; Binch, H.; Knegtel, R.; Golec, J.M.C.; Patel, S.; Charrier, J-D.; Kay, D.; Davies, R.; Li, P.; Wannamaker, M.; Forster, C.; Pierce, A.. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022606 A1 20020321 CAN 136:247582 AN 2002:220582.
42. Golec, J.M. C.; Charrier, J-D.; Knegtel, R.; Bebbington, D.; Davies, R.; Li, P.. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022605 A1 20020321 CAN 136:247581 AN 2002:220581.
43. Davies, R.; Li, P.; Golec, J.M.C.; Bebbington, D. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022603 A1 20020321 CAN 136:247580 AN 2002:220579.
44. Bebbington, D.; Knegtel, R.; Binch, H.; Golec, J.M.C.; Li, P.; Charrier, J-D. Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease. WO 2002022602 A2 20020321 CAN 136:263164 AN 2002:220578.
45. Knegtel, R.; Bebbington, D.; Binch, H.; Golec, J.M.C.; Patel, S.; Charrier, J-D.; Kay, D.; Davies, R.; Li, P.; Wannamaker, M.; Forster, C.; Pierce, A. Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease WO 2002022601 A1 20020321 CAN 136:247579 AN 2002:220577.
46. Vertex inhibitors of Aurora-2, glycogen synthase kinase-3 and Src kinase. Expert Opin. Ther. Patents 2004, 14, 439-443.
47. Aronov, A.; Lauffer, D.J.; Li, H.Q.; Tomlinson, R.C.; Li, P. Preparation of indazolinone compositions useful as kinase inhibitors. WO 2004037814 A1 20040506 CAN 140:391292 AN 2004:370926.
48. Cochran, J.; Nanthakumar, S.; Harrington, E.; Wang, J. Preparation of thiazole compounds as inhibitors of protein kinases. WO 2002096905 A1 20021205 CAN 138:14054 AN 2002:927427.
49. Ledeboer, M.; Wang, J.; Moon, Y.C. Preparation of imidazolpyrimidines and related compounds as JNK protein kinase inhibitors. WO 2004005283 A1 20040115 CAN 140:111414 AN 2004:41465.
50. Green, J.; Arnost, M.J.; Pierce, A. Preparation of pyrazolone derivatives as inhibitors of GSK-3, Aurora-2 and CDK-2. WO 2003011287 A1 20030213 CAN 138:170229 AN 2003:117622.
51. Fancelli, D.; Pittala, V.; Varasi, M. Combinatorial preparation of bicyclo pyrazoles as kinase inhibitors for treatment of cancer and other proliferative disorders. WO 2002012242 A2 20020214 CAN 136:183816 AN 2002:123007.
52. Pevarello, P.; Francelli, D.; Vulpetti, A.; Amici, R.; Villa, M.; Pittala, V.; Ciomei, M.; Mercurio, C.; Roletto, F.; Varasi, M.; Brasca, M.G. 3-Amino-tetrahydropyrrolo[3,4-c]pyrazoles: a New Class of CDK2 Inhibitors. 95th AACR Annual Meeting, Orlando, Florida, USA, 2004.
53. Fancelli, D.; Berta, D.; Bindi, S.; Cameron, A.; Forte, B.; Giordano, P.; Moll, J.; Pittala, V.; Severino, D.; Varasi, M.; Vianello, P. 3-Amino-pyrrolo[3,4-c]pyrazole: Design and Validation of a Novel, Highly Versatile Scaffold for Kinase Inhibition. 95th AACR Annual Meeting, Orlando, Florida, USA, 2004.
54. Tonani, R.; Bindi, S.; Fancelli, D.; Pittala, V.; Danello, M. Preparation of heterobicyclic pyrazole derivatives as kinase inhibitors. WO 2004007504 A1 20040122 CAN 140:111412 AN 2004:60516.
55. Tonani, R.; Bindi, S.; Fancelli, D.; Pittala, V.; Varasi, M Preparation of condensed heterocyclic pyrazole derivatives as protein kinase inhibitors. WO 2004013146 A1 20040212 CAN 140:163864 AN 2004:120860.
56. Damour, D.; Terrier, C.; Nemecek, P. Preparation of indazoles as kinase inhibitors, and their compositions and use for treatment of cancer. FR 2836914 A1 20030912 CAN 139:246026 AN 2003:719201.
57. Walter, R.; Heckel, A.; Roth, G.J.; Kley, J.; Schnapp, G.; Lenter, M.; Van Meel, J.C.A.; Spevak, W.; Weyer-Czernilofsky, U. Preparation of (sulfonylamino)-(aminomethylidene)indolinones as cell proliferation inhibitors. WO 2002036564 A1 20020510 CAN 136:369603 AN 2002:353428.
58. Mortlock, A.A.; Keen, N.J.; Jung, F.H.; Brewster, A.G. Preparation of quinazolines as aurora 2 kinase inhibitors. WO 2001021596 A1 20010329 CAN 134:266317 AN 2001:228866.
59. Mortlock, A.A.; Keen, N.J. Preparation of quinazoline derivatives, method of preparation and use in inhibiting aurora 2 kinase. WO 2001021595 A1 20010329 CAN 134:266316 AN 2001:228865.
60. Mortlock, A.A.; Keen, N.J. Preparation of quinazolines as aurora 2 kinase inhibitors. WO 2001021594 A1 20010329 CAN 134:252355.
61. Mortlock, A.A.; Keen, N.J. Preparation of quinazolines as aurora 2 kinase inhibitors. WO 2001021597 A1 20010329 CAN 134:266318 AN 2001:228867.
62. Mortlock, A.A. Preparation of phosphonooxy quinazoline derivatives as therapeutic agents. WO 2004058782 A1 20040715 CAN 141:123758 AN 2004:566625.
63. Mortlock, A.A.; Jung, F.H. Preparation of 4-[N-(5-pyrimidyl) amino]quinolines as inhibitors of aurora 2 kinase. WO 2001055116 A2 20010802 CAN 135:137521 AN 2001:565012.
64. Berger, D.; Dutia, M.; Powell, D.; Wu, B.; Wissner, A.; Boschelli, D.H.; Floyd, M.B.; Zhang, N.; Torres, N.; Levin, J.; Du, X.; Wojciechowicz, D.; Discafani, C.; Kohler, C.; Kim, S.C., Feldberg, L.R.; Collins, K.; Mallon, R. Synthesis and evaluation of 4-anilino-6, 7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. Bioorg. Med. Chem. Lett. 2003, 18, 3031-4.
65. Mortlock, A.A.; Jung, F.H. Preparation of substituted quinazoline derivatives and their use as inhibitors of AURORA-2 kinase. WO 2002000649 A1 20020103 CAN136:85826 AN 2002:10468.
66. Jung, F.H.; Pasquet, G.R. Preparation of substituted quinazoline derivatives as inhibitors of aurora kinases. WO 2003055491 A1 20030710 CAN 139:101142 AN 2003:532525.
67. Mortlock, A.A. Preparation of quinazolines as inhibitors of Aurora kinase. WO 2004058752 A1 20040715 CAN 141:123646 AN 2004:566600.
68. Jung, F.H.; Pasquet G.R., Preparation of substituted quinazoline derivatives as inhibitors of aurora kinases. WO 2003055491 A1 20030710 CAN 139:101142 AN 2003:532525.
69. Mortlock, A.A.; Jung, F.H. Heron, N.M.; Jung, F.H.; Pasquet, G.R., Preparation of phosphonooxy quinazoline derivatives and their pharmaceutical use. WO 2004058781 A1 20040715 CAN 141:123757 AN 2004:566624.
70. Mortlock, A.A.; Keen, N.J.; Jung, F.H.; Pasquet, G.R.; Lohman, J.J.; Heron, N.M.; Green, S.; Renaud, F.; Boutron, P.; Johnson, T.; Roberts, N.J, Development of a novel series of thiazoloquinazolines which selectively target Aurora kinases. 95th AACR Annual Meeting, Orlando, Florida, USA, 2004.
71. Wilkinson R.W.; Keen, N.J.; Wedge, S.R.; Odedra, R.; Heaton, S.P.; Brown, E.; Brightwell, S.; Jung, F.H.; Heron, N.M.; Mortlock, A.A.; Allen, J.; Kearney, S.; Foster, J.R.; Green, S. Development and characterization of an inhibitor with Aurora A and B specificity. 95th AACR Annual Meeting, Orlando, Florida, USA, 2004.
72. Mortlock, A.A. The Development of Selective Aurora Kinase A and B Inhibitors. Gordon Research Conference - Medicinal Chemistry, New London, NH, 2004.